Intellia Therapeutics (NTLA) Study update summary
Event summary combining transcript, slides, and related documents.
Study update summary
16 Nov, 2026HAELO efficacy and durability
HAELO met its primary and key secondary endpoints; lonvo-z reduced attacks by 87% vs. placebo, all treated participants improved from baseline, and 62% were attack-free. AE-QoL scores fell 23.5 points vs. 6.5 with placebo.
Among 35 participants previously on LTP, attack rates fell 81% during weeks 5–28; 63% achieved complete control vs. 20% whose best response to prior LTP was attack-free.
Across 93 participants given 50 mg, attack rates fell 89% from baseline through up to four years; kallikrein reduction exceeded 80% by month 2 and remained through year 4. All were LTP-free at latest follow-up, and 97% never initiated LTP.
Mean monthly attacks fell from >3 at baseline to <0.5 by month 2 and remained below that level through year 4; >80% were attack-free from month 4 through year 4. In Phase 1/2, at least 90% were attack-free each month through up to four years.
Prespecified subgroups showed consistent benefit; among 32 Phase 1/2 patients, the estimated probability of an attack-free, LTP-free interval lasting at least six months rose from 81% at six months to 93% at 24 months.
Safety and patient outcomes
Lonvo-z was well tolerated, with no new long-term risks identified; common TEAEs included infusion-related reactions, headache, fatigue and nasopharyngitis. HAELO-arm TEAEs were mild or moderate, with no serious adverse events.
Interviews with 23 participants found mean attacks fell from 2.5/month before dosing to 0.1 afterward; all reported well-controlled HAE after treatment vs. 48% before, and 22 described lonvo-z as optimal.
After treatment, 86% redefined control as no symptoms or attacks and less treatment burden; 87% never thought about HAE or did so only when reminded, vs. ~75% who thought about it all the time before treatment.
A 2025 survey of 100 people found 80% had at least one attack in the prior year, 34% reported monthly attacks, nearly 70% cited lifelong medication as a top concern, and insurance access was a major burden.
Regulatory status
FDA accepted the lonvo-z BLA for Priority Review and set a March 10, 2027 PDUFA action date; the agency did not currently plan an advisory committee meeting.
Latest events from Intellia Therapeutics
- Lonvo-z approaches a 2027 decision as launch planning and TTR trials advance.NTLA
Jefferies Global Healthcare Conference - Lonvo-z Priority Review targets a Q1 2027 launch amid continued losses and nex-z safety monitoring.NTLA
Q3 2026 - Late-stage gene editing therapies for HAE and TTR advance, with FDA review and strong market prospects.NTLA
Morgan Stanley 24th Annual Global Healthcare Conference - Strong Phase 3 data and $628.4M cash position support launch plans and ongoing clinical progress.NTLA
Q2 2026 - Accelerated phase III progress in ATTR and HAE, with major data and milestones expected by 2027.NTLA
BofA Securities 2025 Healthcare Conference - Nexi/nex-z achieved deep, durable TTR reduction and clinical stabilization in ATTR amyloidosis.NTLA
Study Update - Strong CRISPR trial progress, $944.7M cash, Q3 net loss $135.7M, late-stage pipeline advancing.NTLA
Q3 2024 - A single 50 mg dose achieved 81% attack reduction and 73% attack-free rate in HAE patients.NTLA
Study Update - Late-stage pipeline progress, restructuring, and cash runway extend operational momentum into 2027.NTLA
Q4 2024